Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price rose 9% during mid-day trading on Tuesday . The stock traded as high as $1.79 and last traded at $1.70, approximately 228,641 shares changed hands during trading. A decline of 30% from the average daily volume of 328,733 shares. The stock had previously closed at $1.56.

CLDX has been the subject of several research reports. Cantor Fitzgerald initiated coverage on Celldex Therapeutics in a report on Thursday, February 20th. They set an “overweight” rating and a $8.00 price target for the company. ValuEngine raised Celldex Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd.

The company has a quick ratio of 6.32, a current ratio of 6.32 and a debt-to-equity ratio of 0.01. The company has a market cap of $28.87 million, a price-to-earnings ratio of -0.47 and a beta of 2.91. The stock has a fifty day moving average price of $2.27 and a two-hundred day moving average price of $2.32.

Several institutional investors have recently bought and sold shares of the stock. TSP Capital Management Group LLC lifted its stake in Celldex Therapeutics by 117.4% in the fourth quarter. TSP Capital Management Group LLC now owns 356,890 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 192,748 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Celldex Therapeutics by 8.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,115,368 shares of the biopharmaceutical company’s stock valued at $2,487,000 after acquiring an additional 89,083 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Celldex Therapeutics during the third quarter valued at approximately $30,000. 24.62% of the stock is currently owned by institutional investors.

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Article: Does the Dogs of the Dow strategy work?

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.